Pharmacy-Driven Diabetes Technology Adoption Will Support A Stronger Long-Term Outlook

AnalystHighTarget

Analyst High Target compiles bullish analysts opinions to create narratives which represent one standard deviation above the consensus price target, using forecasted revenue and earnings figures, as well as the transcripts of earnings calls

Published

03 Feb 26

Updated

26 Jun 26

Views

Not Invested

Shared on 26 Jun 26

Fair value Decreased 27%

BBNX: Mint Launch Timeline And Regulatory Progress Will Drive Future Upside

Beta Bionics’ outlook shifts as analyst targets come down, even while some still see a clear path to upside if the Mint patch pump stays on track and regulators remain supportive. New product updates also bring both momentum and fresh safety questions, with software-related recalls now in focus.

2 views

Fair Value vs Share Price

US$29.19

vs US$15.1748.0% undervalued

41.2%

Revenue growth

11.9%

Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on Beta Bionics

Fair value estimate changes
Narrative and analyst updates
Key company announcements

Company analysis

Flawless balance sheet with limited growth.

Market capUS$704.1m

PB2.5x

Estimated Growth25.7%

Dividend YieldN/A

Full analysis

CEO & management

Sean Saint

CEO

3.7yrs

CEO Tenure

A commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes.